Eulav Asset Management Bristol Myers Squibb CO Transaction History

Eulav Asset Management

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 06, 2021	SELL	$61.91 - $67.42 $8.36 Million - $9.11 Million	-135,084 Closed	0 $0
Q1 2021 Apr 30, 2021	SELL	$59.34 - $66.74 $1.19 Million - $1.33 Million	-19,994 Reduced 12.89%	135,084 $8.53 Million
Q4 2020 Feb 16, 2021	SELL	$57.74 - $65.43 $1.15 Million - $1.3 Million	-19,922 Reduced 11.38%	155,078 $9.62 Million
Q3 2020 Nov 05, 2020	SELL	$57.43 - $63.64 $863,976 - $957,400	-15,044 Reduced 7.92%	175,000 $10.6 Million
Q2 2020 Aug 11, 2020	BUY	$54.82 - $64.09 $6.58 Million - $7.69 Million	119,990 Added 171.28%	190,044 $11.2 Million
Q1 2020 Apr 27, 2020	SELL	$46.4 - $67.43 $693,494 - $1.01 Million	-14,946 Reduced 17.58%	70,054 $3.91 Million
Q4 2019 Feb 13, 2020	SELL	$49.21 - $64.19 $147,630 - $192,570	-3,000 Reduced 3.41%	85,000 $5.46 Million
Q3 2019 Nov 12, 2019	SELL	$42.77 - $50.71 $513,240 - $608,520	-12,000 Reduced 12.0%	88,000 $4.46 Million
Q2 2019 Aug 05, 2019	BUY	$44.62 - $49.34 $1.34 Million - $1.48 Million	30,000 Added 42.86%	100,000 $4.54 Million
Q1 2019 May 13, 2019	BUY	$45.12 - $53.8 $3.16 Million - $3.77 Million	70,000 New	70,000 $3.3 Million

2,536

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $120B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Eulav Asset Management, based on Form 13F filings with the SEC.

Stay updated on Eulav Asset Management with notifications on news.